Back to top
more

bluebird bio (BLUE)

(Real Time Quote from BATS)

$1.00 USD

1.00
5,681,349

+0.06 (6.90%)

Updated Jul 9, 2024 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 7.61% and 147.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season?

by Zacks Equity Research

bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for Ensign Group's (ENSG) Earnings in Q1?

by Zacks Equity Research

Ensign Group's (ENSG) Q1 results are likely to reflect a better revenue stream.

bluebird bio (BLUE) Catches Eye: Stock Jumps 6%

by Zacks Equity Research

bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA

by Zacks Equity Research

Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.

Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line

by Zacks Equity Research

bluebird (BLUE) reports a wider-than-expected loss and in-line revenues for the fourth quarter of 2019.

Bluebird Bio (BLUE) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bluebird Bio (BLUE) closed at $91.77, marking a +1.75% move from the previous day.

Novo Nordisk's Shares Up in a Year on Pipeline Progress

by Zacks Equity Research

Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.

bluebird (BLUE) Catches Eye: Stock Jumps 6.8%

by Zacks Equity Research

bluebird (BLUE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

by Zacks Equity Research

The biotech sector witnesses pipeline updates from the annual ASH meet.

Fate (FATE) Announces Encouraging Data on Immunotherapies

by Zacks Equity Research

Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.

bluebird Reports Positive Top-Line Data on Myeloma Drug

by Zacks Equity Research

bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.

Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock?

by Zacks Equity Research

Investors need to pay close attention to bluebird (BLUE) stock based on the movements in the options market lately.

Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD

by Zacks Equity Research

Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.

Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease

by Zacks Equity Research

Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.

Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of -5.67% and -15.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment

by Zacks Equity Research

Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.

bluebird Inks Genome Editing Research Deal With Novo Nordisk

by Zacks Equity Research

bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.

FDA Grants Priority Review to Global Blood's SCD Candidate

by Zacks Equity Research

The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.

Bluebird (BLUE) Down 19.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

bluebird (BLUE) posts wider-than-expected loss, while sales beat estimates in the second quarter of 2019.

Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of -17.16% and 25.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?